The Life Cycle Of Medical Ideas

Identifies a "grey medicine" zone between proven and disproven: promising, biologically-plausible treatments (Zamboni's MS surgery, the Gat-Goren prostate procedure, minocycline for schizophrenia's negative symptoms) that linger un-adopted. Reframes the problem: medications are "pre-suppressed" by the cost/burden of proof and medical conservatism, and drug companies merely pay to "un-suppress" the profitable ones - so cheap, unpatentable treatments stall.

Quality 66 · Strong. A genuinely useful reframe ("pre-suppression", "grey medicine") with good case studies, though exploratory and inconclusive by design. Mid-Strong.

Claude’s paradigm shift 45 · Moderate. A moderately fresh reframing of the why-don't-we-use-cheap-cures problem, building on familiar health-economics ideas. Moderate.

Real-world impact 2 · Minor. A useful reframe ('grey medicine' / 'pre-suppression' of cheap unpatentable treatments); illuminates the medical-system discourse but moves no policy or practice → RWI 2.